Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Supernus Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Supernus Pharmaceuticals achieved Milestone 1 under its Contingent Value Right Agreement on March 18, 2026, triggering a $33.4 million cash payment obligation ($0.50 per CVR). This represents a significant near-term cash outflow that investors and stakeholders should monitor for impact on the company's liquidity and financial position.
Key Takeaways
Milestone 1 achievement under CVR Agreement was reached on March 18, 2026, with formal reporting on May 17, 2026
Company must pay $33.4 million in cash ($0.50 per CVR) subject to applicable withholding taxes
2 more takeaways